Table 1.

Baseline characteristics of 25 participants with intradialytic hypertension enrolled into the Mechanisms and Treatment of Intradialytic Hypertension studya

CharacteristicIntradialytic Hypertension (n=25)
Age (yr)53.9 (±11.1)
Male sex20 (80)
Black race versus other9 (36)
Hispanic ethnicity16 (64)
Current tobacco use5 (20)
Dialysis duration <1 yr9 (36)
Comorbid conditions
 diabetes mellitus22 (88)
 cardiovascular diseaseb8 (32)
 congestive heart disease4 (16)
 hypertension25 (100)
 autoimmune disorder2 (8)
 atrial flutter or fibrillation0 (0)
Antihypertensive medications
 ether ACE-I or ARB or both16 (64)
 β blocker (including labetalol)17 (68)
 calcium channel blocker15 (60)
 clonidine8 (32)
 hydralazine6 (24)
 nitroglycerin or isosorbide0 (0)
Other medications
 aspirin10 (40)
 cinacalcet HCL6 (24)
 erythropoiesis-stimulating agents22 (88)
 intravenous iron22 (88)
 vitamin D analogs21 (84)
 calcium-containing phosphorus binder14 (56)
 noncalcium-containing phosphorus binder11 (44)
 cholesterol lowering agents12 (48)
 clopidogrel2 (8)
 phosphodiesterase type 5 inhibitors2 (8)
  • Values are reported as mean ± SD or n (%). ACE-I angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.

  • a Compared with patients who refused participation (n=27), participants were slightly younger (53.9 versus 56.6 years) and more likely to be male (80% versus 44%).

  • b Either coronary artery disease, cerebrovascular disease, or peripheral vascular disease.